Press Releases

DNATRIX COMPLETES $20 MILLION SERIES B FINANCING

Posted on October 14, 2014

San Diego, Calif.  –October 14, 2014 – DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing.  New investor Morningside Ventures led the.. read more

FDA GRANTS ORPHAN DRUG DESIGNATION TO DNATRIX’S DNX-2401 FOR THE TREATMENT OF MALIGNANT GLIOMA

Posted on October 7, 2014

SAN DIEGO, CA. – October 7, 2014 – DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation.. read more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 IN RECURRENT GLIOBLASTOMA TRIAL

Posted on September 16, 2014

HOUSTON, TX. – September 15, 2014 – DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company’s lead product, DNX-2401, a replication.. read more

FDA GRANTS FAST TRACK STATUS TO DNATRIX DRUG DNX-2401 FOR RECURRENT GLIOBLASTOMA

Posted on June 17, 2014

SAN DIEGO, CA. – June 17, 2014 – DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status.. read more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas

Posted on February 24, 2014

Grant to Be Used to Fund Ongoing Clinical Trials for Brain Cancer HOUSTON, TX – February 24, 2014 — DNAtrix Inc., a biotech company focusing on the development of oncolytic.. read more